Alpha Tau Medical presented clinical results of its alpha radiation cancer treatment at ASTRO

Alpha Tau Medical Ltd., (Israel) presented preliminary clinical results of its alpha-radiation-based brachytherapy (Alpha DaRT) at ASTRO (American Society for Therapeutic Radiation Oncology) on October 23 in San Antonio, Texas, USA. HekaBio has partnered with Alpha Tau Medical to develop and commercialize the Alpha DaRT cancer treatment for solid tumors in Japan.

The clinical results carried out in Israel were from 15 subjects who completed follow-up for 30-45 days, resulting in an overall response rate of 100% and a complete response rate over 73%. Some of the subjects were elderly patients who were medically unfit for surgery or failed previous external beam radiation. It was demonstrated that the Alpha DaRT can be administered safely under local anesthesia in an outpatient setting for all of the patients, including the given sensitive cases.

Please refer to the attached poster for the content of the clinical trial.

About Alpha Tau Medical LTD

Alpha Tau Medical is an Israeli medical device company that focuses on research, development and commercialization of Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) for the treatment of solid tumor cancers. The Alpha DaRT technology was developed by Prof. Itzhak Kelson and Prof. Yona Keisari in 2003 at Tel Aviv University. The company strives “to enable a cancer treatment that destroys tumors while sparing healthy tissue to save the lives of millions of patients around the world.” (Alpha Tau Medical, Mission Statement)

For more information, please visit

About Alpha DaRT

The Alpha DaRT has several important advantages:

• Highly potent and conformal

• Proven efficacy for all solid tumors tested

• Stimulates anti-tumor immune response

• Low toxicity, no known negative systemic effects

• Effective regardless of tumor oxygen level

• Short half-life – quick clinical outcome

• Single-session treatment

• Enables combination with other therapies or reapplication

• Disposable applicators - does not require capital equipment or special shielding




ヘカバイオ株式会社(東京都中央区日本橋本石町3-3-16)は2021年1月29日付にて4億円の第三者割当増資を行いました。 今回の増資により調達した資金は、今後当社が開発を手掛けるポートフォリオを拡充させるために活用いたします。 当社は、人々の医療と健康への貢献を使命として、世界への窓口として日本にベースに置き、海外の製品の導入に特化して開発や市場化を行っています。がん、線維性疾患、自己免疫性炎症


~バイオサイエンスの新たなイノベーションについて認知度とアクセシビリティの向上を図る~ 2020年9月23日 ヘカバイオ株式会社(本社:東京都中央区、代表取締役兼CEO:クレア・ロバート、以下:ヘカバイオ)と株式会社コスモ・ピーアール(本社:東京都港区、代表取締役社長:佐藤玖美、以下:コスモ)は、コスモがヘカバイオに出資し、両社が戦略的パートナーシップを締結したことを発表します。本パートナーシップ

オフィス移転のお知らせ Office Relocation

2020年8月24日より下記へ移転いたします。 〒103-0021 東京都中央区日本橋本石町3丁目3番16号 日本橋室町ビル8階 電話番号・FAX番号 変更無し 最寄り駅: 地下鉄各線 三越前駅 A8出口 徒歩3分 Effective August 24, 2020, HekaBio will relocate to new premises as follows. Nihonbashi Muro





© 2020 HekaBio K. K.​